Zenas BioPharma
ZBIO
23.85
-1.19
-4.75%
Zenas BioPharma
US · ZBIO
#2856 by market cap
Listed 2024
23.85
-1.19
-4.75%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Analysts Offer Insights on Healthcare Companies: Zenas BioPharma, Inc. (ZBIO) and Atai Beckley N.V. (ATAI)TipRanks · 2026/6/27
-
Rating change
Guggenheim Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/8/14
-
Rating change
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32Market Newswire · 2026/8/17
-
Rating change
Wedbush Keeps Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/8/14
-
Rating change
Citi Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/9/11
-
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Maintains Target Price $32Market Newswire · 2026/11/6
-
Rating change
Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/8/14
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Zenas BioPharma, Inc. (ZBIO), Ocular Therapeutix (OCUL)TipRanks · 2026/10/13
-
Rating change
Citi Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $41Market Newswire · 2026/9/11
-
Rating change
Analysts Offer Insights on Healthcare Companies: MDxHealth (MDXH), Opko Health (OPK) and Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/8/14
-
Morgan Stanley Initiates Zenas BioPharma(ZBIO.US) With Hold Rating, Announces Target Price $32Market Newswire · 2026/10/28
-
Rating change
H.C. Wainwright Keeps Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/9/22
-
Rating change
Wedbush Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/8/14
-
Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q3 Revenue $10.0MMT Newswires · 2026/11/5
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: DocGo (DCGO), Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/9/30
-
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44Market Newswire · 2026/11/9
-
Rating change
Wedbush Remains a Buy on Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/10/13
-
Citi Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/10/28
-
Rating change
Zenas BioPharma, Inc. (ZBIO) Receives a Buy From GuggenheimTipRanks · 2026/8/14
-
Rating change
Citi Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Raises Target Price to $48Market Newswire · 2026/9/30
-
Rating change
Analysts' Top Healthcare Picks: Zenas BioPharma, Inc. (ZBIO), Entrada Therapeutics Inc (TRDA)TipRanks · 2026/6/3
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/6/11
-
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44Market Newswire · 2026/10/28
-
Citi Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/10/13
-
Rating change
Wedbush Initiates Zenas BioPharma(ZBIO.US) With Buy Rating, Announces Target Price $45Market Newswire · 2026/5/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Zenas BioPharma discussion 0 comments